Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
Potential received 3rd dose of Shingrix; This non-serious case was reported by a other health professional via sales rep and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on an unknown date) and Shingrix (received 2nd dose on an unknown date). On an unknown date, the patient received the 3rd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Potential received 3rd dose of Shingrix). The outcome of the extra dose administered was not applicable. Additional Information: GSK receipt date: 17-APR-2025 The field representative reported that what was the reports if a patient gets a 3rd dose of shingrix, because they did not remember that they already had two doses when they got the 3rd. The patient received 3rd dose of Shingrix which led to, extra dose administered.